Skip to main content

Table 1 Characteristics of the included studies in the meta-analysis

From: Can 68Ga-prostate specific membrane antigen positron emission tomography/computerized tomography provide an accurate lymph node staging for patients with medium/high risk prostate cancer? A diagnostic meta-analysis

References

Country

Study design

Study population

Recruiting time

Uptake time (min)

Lymphade-nectomy

Age Median (range) Median (IQRe)

PSAd median (range) Median (IQR)

Patient characteristics

Budaus [25]

Germany

Retrospective

Single center

June. 2014 to Mar. 2015

NA

ePLNDf

63 (44–75)

8.8 (1.4–376)

High risk

Herlemann [20]

Germany

Retrospective

Single center

Jan. 2014 to Aug. 2015

60

PLNDg

70.5 (59–80)b

56 (3.3–36.3)b

4 intermediate risk and 16 high risk

Maurer [24]

Germany

Retrospective

Single center

Dec. 2012 to Nov. 2014

59.8 ± 17.8a

PLND

66 (45–84)

11.6 (0.57–244)

42 intermediate risk and 88 high risk

Gupta [22]

India

Retrospective

Single center

Dec. 2014 to Dec. 2015

Nearly 60

ePLND

NA

NA

High risk

Obek [21]

Turkey

Retrospective

Single center

July. 2014 to Oct. 2015

45–60

ePLND

64 ± 6.0a

26.5 ± 21.4a

44 high risk and 7 very high risk

Van Leeuwen [26]

Australia

Prospective

Single center

Apr. to Oct. 2015

60

ePLND

65 (60–71)

65 (55–82)

3 intermediate risk and 27 high risk

Zhang [12]

China

Retrospective

Single center

Mar. to July. 2017

60

PLND

69 (55–82)

37.25 (7.2–348)

17 intermediate risk and 25 high risk

Van Leeuwen [2]

Australia

Retrospective

Single center

Feb. 2015 to Oct. 2017

60

ePLND

NA

9.4

140 intermediate risk and high risk

Yilmaz [23]

Turkey

Retrospective

Single center

May. 2016 to Apr. 2018

Approximately 60

rLNDc

62.8 (49–73)b

12 (2.4–32)b

15 intermediate risk and 6 high risk

Yaxley [13]

Australia

Retrospective

Single center

July. 2014 to Sep. 2017

45–60

PLND

68 (44–80)

7.6 (1.5–51)

85 intermediate risk and 123 high risk

  1. aMean ± SD
  2. bMean (range)
  3. crLND, regional lymph node dissection
  4. dPSA, prostate specific antigen
  5. eIQR, interquartile range
  6. fePLND, extend pelvic lymph node dissection
  7. gPLND, pelvic lymph node dissection